Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
Stopped early · Phase 1/Phase 2
Conditions studied: Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Advanced Solid Tumor, Refractory Tumor, Metastatic Tumor
In brief
This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.
Key facts
- Study ID
- NCT05099549
- Run by
- NKGen Biotech, Inc.
- People needed
- 11
- Starts
- 2021-11-03
- Expected to finish
- 2023-09-21
- Last updated by the study team
- 2024-03-01
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- USC/Norris Comprehensive Cancer Center — Los Angeles, California, United States
- Sarcoma Oncology Center — Santa Monica, California, United States
- University of Chicago — Chicago, Illinois, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.